Press Release Details

Cerus Corporation Invites You to Join a Webcast of its Second Quarter Financial Results Conference Call

July, 22 2004

CONCORD, Calif. -- In conjunction with Cerus Corporation's (Nasdaq:CERS) report of its second quarter financial results, you are invited to listen to its conference call that will be broadcast live over the Internet on July 29, 2004 at 4:30 p.m. ET with Claes Glassell, President and CEO and Gregory Schafer, Chief Financial Officer.

What: Cerus Corporation second quarter financial results with an update on progress and future outlook When: Thursday, July 29, 2004 at 4:30 p.m. ET Where: 
How: Live over the internet -- Simply log on to the web at the address above
Contact: Alexandra Santos / Cerus Corporation, 925-288-6156

The conference call is protected by copyright. It cannot be recorded or rebroadcast without Cerus' permission.

Cerus Corporation is developing novel technologies to provide safer and more effective options to patients in areas with substantial unmet medical needs. The Concord, California-based company is pursuing a novel therapeutic vaccine technologies to harness the power of the immune system against cancer and infectious disease. In collaboration with MedImmune, Inc., Cerus is developing a therapeutic vaccine designed to target antigens expressed in breast, prostate and colon cancer, as well as metastatic melanoma. Cerus is also collaborating with subsidiaries of Baxter International Inc. on the INTERCEPT Blood System, designed to enhance the safety of the world's blood supply by inactivating viruses, bacteria, other pathogens and white blood cells. The INTERCEPT Blood System is based on the company's Helinx technology for controlling biological replication.

Helinx is a trademark of Cerus Corporation

INTERCEPT Blood is a trademark of Baxter International, Inc.

If you are unable to participate during the live webcast, the call will be temporarily archived on the Website


    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600